NAPRO , was bringt die Zukunft ????? - 500 Beiträge pro Seite

[JS222]

NaPro to Sell Worldwide Paclitaxel Business
via COMTEX

April 9, 2003

BOULDER, Colo., Apr 9, 2003 /PRNewswire-FirstCall via COMTEX/ --

NaPro BioTherapeutics, Inc., (Nasdaq: NPRO) announced today that it is offering for sale its worldwide generic cremaphor injectable paclitaxel business. Proceeds from the sale will be used to accelerate the development and commercialization of therapeutic products based upon NaPro`s proprietary Gene Editing and Targeted Oncology platforms, to advance the company`s reagent and services business, and to retire $20.0 million of funded debt from Abbott Laboratories.

NaPro`s paclitaxel business generated $34.2 million in product sales and $10.2 million in gross profit in 2002, up from $15.7 million in product sales and a gross loss of $3.6 million for 2001. The assets to be sold include more than one hundred domestic and international issued and pending paclitaxel patents, a worldwide registration dossier, worldwide development and supply agreements, inventories, and manufacturing fixed assets. The Company has retained Wells Fargo Securities, LLC to represent NaPro in this transaction.

`Our worldwide generic paclitaxel business is strong. Our decision to sell the business now arises from our conviction that the much larger, long- term opportunity for NaPro shareholders lies in the commercialization of the unique therapeutic candidates we have in development,`commented Leonard P. Shaykin, Chairman and Chief Executive Officer of NaPro.

`The net proceeds from the sale of the paclitaxel business will accelerate the development of our therapeutic programs and support the growth of our reagent and services business. We anticipate the sale of the paclitaxel business should be completed by the fourth quarter of this year, and will likely require approval by the Company`s stockholders at a special meeting convened for that purpose,`continued Mr. Shaykin.

Neither the timing nor the terms of a sale of the paclitaxel business are certain at this time, and the Company can give no assurance that any transaction will occur. NaPro, therefore, does not intend to further comment on the status of the sales effort prior to signing and announcing a definitive agreement.

NAPRO`S DRUG DEVELOPMENT PROGRAMS

NaPro currently has four proprietary therapeutic product candidates in preclinical development. These four product candidates are representative of two patented platform technologies in the area of Gene Editing and Targeted Oncology.

Gene Editing Development Programs

NaPro is currently developing an ex vivo therapy for Sickle Cell disease based upon NaPro`s proprietary Gene Editing technology which employs proprietary oligonucleotides that are able, among other things, to rapidly locate and specifically modify a chosen single base pair in a targeted gene of choice. The Company`s therapy consists of treating hematopoietic progenitor cells, isolated from Sickle Cell patients which are then treated ex vivo, with a proprietary oligonucleotide that corrects the defective base pair in the hemoglobin gene. The resulting corrected autologous progenitor cells, when re-introduced into the patient, would then begin producing normal, rather than sickle, hemoglobin. The therapy addresses the underlying genetic basis of the disease.

The unique attributes of NaPro`s Gene Editing technology are that it does not rely upon the random insertion of any genetic material, is specific to the individual base pair, and does not employ a vector, viral or otherwise, to induce genetic correction. The company believes that, consequently, it will not give rise to the toxicities associated with traditional gene therapy.

NaPro is also developing an in vivo oligonucleotide therapy for Huntington`s disease. Huntington`s disease is a neurodegenerative disease that is specifically characterized by fatal aggregate formation and cell death in most areas of the brain. There is no current treatment to halt the progression of the disease, which leads to death after ten to twenty-five years of decline. NaPro has patented proprietary oligonucleotides that may be effective in addressing the treatment paradigm for this disease. Both the Sickle Cell and the Huntington`s program are in pre-clinical development and will require significant additional work before entering the clinic.

The company`s Gene Editing technology also underpins an additional set of business opportunities for NaPro in the area of research reagents and genomic services. The Company now offers a service to researchers to rapidly isolate hard to detect genes and gene fragments in a diverse and heterogeneous genetic population. The Company is also offering SNP and haplotype panels in any gene of choice, quickly and cost effectively, for diagnostic uses and transfer into cells or animal models for target validation, drug safety and efficacy assays and for studies of gene function.

Targeted Oncology Development Programs

NaPro currently has two candidate molecules in pre-clinical development in the oncology area. Both of these products are based on the Company`s Targeted Oncology technology, which links chemotherapeutic agents to peptides which target specific tumors. The advantage of this technology is that the molecules may have both a better safety and efficacy profile than untargeted chemotherapeutic agents because of their unique tumor specificity. The first is a proprietary molecule targeted to receptors for squamous cell cancers of the head and neck, and the second is a proprietary molecule targeted to specific receptors over-expressed in both small-cell lung and pancreatic cancers. Both targeted oncology programs are in pre-clinical development and will require significant additional work before entering the clinic.

Conference Call Information

NaPro management will host a conference call with investors and analysts to discuss the sale of the paclitaxel business. The call will take place on April 10 at 8:30am EDT and can be accessed by dialing [phone] for domestic callers, and for international callers, [phone]. The pass code is NAPRO. The conference call will also be available on the Company`s website at www.naprobio.com .

A replay of the conference call will be available from 10:30am EDT on April 10, 2003 through April 16 11:59pm EDT and may be accessed by dialing [phone] for domestic callers and for international callers, [phone].

NaPro BioTherapeutics, Inc. is a pharmaceutical company focused in two distinct research, development and marketing areas: the development and in- licensing of novel pharmaceutical products, primarily in the area of anti- cancer agents, and the development of novel genomic technologies, primarily in the area of `gene editing,`for application in human therapeutics, diagnostics, agribiotechnology, and pharmacogenomics.

The statements in this news release that are not historical facts, including those regarding the sale of the paclitaxel business and the success of NaPro`s development programs. These are forward-looking statements that represent management`s beliefs and assumptions as of the date of this news release, based on currently available information. Forward-looking statements can be identified by the use of words such as `believes,``intends,` `estimates,``may,``will,``should,``anticipated,``expected,``trusts`or comparable terminology or by discussions of strategy. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it cannot assure that these expectations will prove to be correct. Such statements involve risks and uncertainties as to which there can be no assurance, including, but not limited to the ability of the Company to sell the paclitaxel business for an adequate and acceptable price, the costs of continuing development of any or all of the Company`s development programs, the timing of when those programs will enter the clinic, the successful commercialization of the Company`s platform technologies, the ability to obtain, maintain and enforce patents relating to the Company`s platform technologies, and the risk that developments in the Company`s business will require new and unanticipated investment. Should one or more of these risks materialize (or the consequences of such a development worsen), or should the underlying assumptions prove incorrect, actual results can differ materially from those forecasted or expected. These factors are more fully described in the Company`s documents filed from time to time with the Securities and Exchange Commission, which are incorporated by reference, including the Company`s form 10-K for the year ending December 31, 2002 filed with the Securities and Exchange Commission on March 27, 2003. The Company disclaims any intention or obligation to update publicly or revise such statements whether as a result of new information, future events or otherwise.

For further information, please contact L. Robert Cohen Vice President, Investor Relations of NaPro BioTherapeutics, Inc. [phone]; or Investors, Lilian Stern of Stern Investor Relations, [phone], for NaPro BioTherapeutics, Inc.; or Media, Linda Dyson, of Signova, [phone], for NaPro BioTherapeutics, Inc.

SOURCE NaPro BioTherapeutics, Inc.

L. Robert Cohen Vice President, Investor Relations of NaProBioTherapeutics, Inc. [phone]; or Investors, Lilian Stern of SternInvestor Relations, [phone], for NaPro BioTherapeutics, Inc.; orMedia, Linda Dyson, of Signova, [phone], for NaPro BioTherapeutics,Inc.
http://www.naprobio.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[JS222]

RAiDAR alerts Learn More About RAiDAR-LT


04/09/2003 (16:30 ET) NaPro to Sell Worldwide Paclitaxel Business - PR Newswire



04/09/2003 (09:51 ET) NaPro Biotherapeutics Announces Sale of Technical and Analytical Services Group to ChromaDex - PR Newswire



03/27/2003 (09:00 ET) NaPro BioTherapeutics Licenses Peptide Targeting Technology From The University of Texas M. D. Anderson Cancer Center - PR Newswire



03/27/2003 (08:10 ET) New 10-K just released for NPRO - Edgar



03/27/2003 (08:10 ET) New 8-K just released for NPRO - Edgar



03/26/2003 (12:26 ET) VOLUME(+): NPRO Volume 22% > 20-adsv, Stock +17.39% - Knobias


JS200

[JS222]

Von Gestern

NPRO
NAPRO BIOTHERAPEUTICS INC
0.730
+0.020 +2.82%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 4/2/2003 (7) days ago, when the stock price was 0.720. Since then the stock gained 1.39% .

Today the stock closed higher with an unchanged high and a higher low. The volume is extremely low. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Spinning Top

Today a Spinning Top formed. Both the bulls and the bears were active during the session. Even though the session opened and closed with little change, prices moved significantly higher and lower in the mean time. Be careful, this indicates weakness among the bulls and a potential change or interruption in the current trend!

Stock Quote
Last 0.730
Previous Close 0.710
Change +0.020
% Change +2.82%
Volume 81,150
Stock Activity
Open 0.720
Day`s High 0.740
Day`s Low 0.690
52 Week High 9.239
52 Week Low 0.300

Stock Price History
3 Month % Change 35.19
6 Month % Change -34.23
12 Month % Change -90.62
Stock Statistics
50 Day Close MA 0.516
200 Day Close MA 1.639
65 Day Volume MA 210,848

JS200

[JS222]

NaPro to sell worldwide paclitaxel business

Thursday , April 10, 2003 09:30 ET

Apr 10, 2003 (Datamonitor via COMTEX) -- NaPro BioTherapeutics is offering for sale its worldwide generic cremaphor injectable paclitaxel business.

Proceeds from the sale will be used to accelerate the development and commercialization of therapeutic products based upon NaPro`s proprietary Gene Editing and Targeted Oncology platforms, to advance the company`s reagent and services business, and to retire $20 million of funded debt from Abbott Laboratories.

NaPro`s paclitaxel business generated $34.2 million in product sales and $10.2 million in gross profit in 2002, up from $15.7 million in product sales and a gross loss of $3.6 million for 2001. The assets to be sold include more than one hundred domestic and international issued and pending paclitaxel patents, a worldwide registration dossier, worldwide development and supply agreements, inventories, and manufacturing fixed assets.

"Our worldwide generic paclitaxel business is strong. Our decision to sell the business now arises from our conviction that the much larger, long- term opportunity for NaPro shareholders lies in the commercialization of the unique therapeutic candidates we have in development," commented Leonard P Shaykin, chairman and CEO of NaPro.

"The net proceeds from the sale of the paclitaxel business will accelerate the development of our therapeutic programs and support the growth of our reagent and services business. We anticipate the sale of the paclitaxel business should be completed by the fourth quarter of this year, and will likely require approval by the company`s stockholders at a special meeting convened for that purpose," added Mr Shaykin in comments to the press.


URL: http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon


Copyright (C) 2003 Datamonitor. All rights reserved


-0-


KEYWORD: United States
SUBJECT CODE: All cancer
Pharmaceuticals
NaPro BioTherapeutics, Inc.
Cancer, General

JS200

[JS222]

NaPro, um weltweites paclitaxel-Unternehmen zu verkaufen,

Donnerstag 10. April 2003 09:30 ET

10. April 2003 Datamonitor über COMTEX, NaPro BioTherapeutics bietet sein weltweites cremaphor injectable paclitaxel-Unternehmen ohne Markennamen für Verkauf an.

Erlös des Verkaufes werden benutzt werden, um die Entwicklung und die Kommerzialisierung therapeutischer Produkte zu beschleunigen, die nach NaPro`s gesetzlich geschützter Genänderung basiert werden, und auf Onkologieplattformen, das Reagens und das Dienste-Unternehmen der Gesellschaft, und $20 Millionen von finanzierten Schulden von Abbott Laboratories zu pensionieren, voranzubringen, abgezielt werden.

NaPro`s paclitaxel-Unternehmen erzeugte $34.2 Millionen in Produktverkäufen und $10.2 Millionen in unfeinem Gewinn in 2002, auf von $15.7 Millionen in Produktverkäufen und einem unfeinen Verlust von $3.6 Millionen an 2001. Die Vermögenswerte, die verkauft werden sollten, schließen mehr ein, als ein hundert häusliches und internationales ausgab, und bis zu paclitaxel-Patenten, eine weltweite Registrierungsakte, weltweite Entwicklung und liefert Einverständnisse, Inventare und Erzeugung reparierten Vermögenswerte.

"Unser weltweites paclitaxel-Unternehmen ohne Markennamen ist stark. Unsere Entscheidung, zu verkaufen, daß das Unternehmen jetzt aus unserer Überzeugung entsteht, der das viel Größere, lang, Begriff Gelegenheit für NaPro-Aktionäre Lügen in der Kommerzialisierung der einmaligen therapeutischen Bewerber wir haben uns in Entwicklung, Leonard P Shaykin, Vorsitzenden und DIREKTOR von NaPro, geäußert."

"Der netto Erlös des Verkaufes des paclitaxel-Unternehmens werden die Entwicklung unserer therapeutischen Programme beschleunigen und den Wuchs von unserem Reagens und unserem Dienste-Unternehmen unterstützen. Wir erwarten, der Verkauf des paclitaxel-Unternehmens sollte bis zum vierten Viertel dieses Jahres vervollständigt werden, und wird wahrscheinlich bei einer besonderen Versammlung, die für diesen Zweck" einberufen wird, Zustimmung der Gesellschaftsaktionäre verlangen, fügte Mr Shaykin in Stellungnahmen der Presse hinzu.


URL: http://www.datamonitor.com
Wiederveröffentlichung oder Neuverteilung, einschließlich durch das Rahmen oder ähnliche Mittel,
wird ausdrücklich ohne vorausgehende geschriebene Zustimmung verboten. Datamonitor wird nicht verantwortlich für Fehler oder Verzögerungen im Inhalt sein, oder für irgendwelche darauf in Vertrauen ergriffene Handlungen


Copyright (C) 2003 Datamonitor. Alle Rechte reserviert


-0 -


STICHWORT: Verbundene Staaten
STAATSBÜRGER CODE: Aller Krebs
Arzneimittel
NaPro BioTherapeutics, Inc.
Krebs, General,
JS200

[JS222]

04/10/2003 (11:13 ET) VOLUME(-): NPRO Volume 18% > 20-adsv, Stock -26.03% - Knobias
04/10/2003 (09:30 ET) NaPro to sell worldwide paclitaxel business - Datamonitor
04/09/2003 (16:30 ET) NaPro to Sell Worldwide Paclitaxel Business - PR Newswire
04/09/2003 (09:51 ET) NaPro Biotherapeutics Announces Sale of Technical and Analytical Services Group to ChromaDex - PR Newswire
03/27/2003 (09:00 ET) NaPro BioTherapeutics Licenses Peptide Targeting Technology From The University of Texas M. D. Anderson Cancer Center - PR Newswire

JS200

[JS222]

VOLUME(-): NPRO Volume 21% > 20-adsv, Stock -8.77%

Friday , April 11, 2003 11:51 ET

This is the 2nd VOLUME alert for NPRO in the past 7 calendar days.

Trading for NaPro BioTherapeutics Inc (NASDAQ NM: NPRO) has been heavier than usual in today`s session. By 11:50 ET, the stock had already traded 168,100 shares via 122 trades. The cumulative volume is 21.40% above its 20-day average of 138,463. Normally the stock experiences around 139 individual trades per session.

So far, today`s volume surge has caused a net decline in NPRO`s stock price. At the time of this alert, the stock was trading at $0.520, down $-0.050 (-8.77%).

One year ago, the Company`s shares closed at $8.850. The price has declined more than 94 percent since then.

Over the last 10 trading session NPRO has traded in a range between $0.540 and $0.780 and is currently trading 94.51% below its 52-week high of $9.480 set on April 16, 2002 and 92.59% above its 52-week low of $0.270 from February 20, 2003.

In the previous 3 sessions, NPRO trading has displayed a mixed trend. Closing results have been as follows:

April 10, 2003 --- closed at $0.570 down $0.160 (-21.92%) on 410,500 shares
April 09, 2003 --- closed at $0.730 up $0.020 (+2.82%) on 82,350 shares
April 08, 2003 --- closed at $0.710 down $0.010 (-1.39%) on 128,700 shares

The Company last released news on April 09, 2003:

"NaPro to Sell Worldwide Paclitaxel Business"

NAPRO BIOTHERAPEUTICS INC
NaPro BioTherapeutics, Inc., headquartered in Boulder, Colorado, is a biopharmaceutical company focused on the development, production and licensing of anti-cancer compounds, complex natural-product pharmaceuticals as well as the development and licensing of novel genomic technologies for applications in human therapeutics and diagnostics, pharmacogenomics and agrobiotechnology. To date, all of the Company’s sales have been of one product, Paclitaxel (generic Taxol(R)), a widely prescribed anticancer drug, which is derived from extractions from yew trees of which supplies are limited.

JS200

[tomtom11]

Hallo,

womit ist der Anstieg in den letzten Tagen begründet? Gibt es irgendwelche Neuigkeiten?

t.t.

[drachentier]

Guten,morgen!...Ist,die Abwärtsbewegung jetzt gestoppt?? Immerhin 50% an Wert verloren vom hoch...Hatte,napro mal zu 0,30!!-na,ja,aber ist die Aktie jetzt noch ein Kauf??...Danke für Antworten!!-Lieb grüß Drachi

[js200]

http://www.investtech.com/nasdaq/ana/npro.htm

JS200

[drachentier]

Danke,für den link!...super,Chartanalyse,aber ich sehe Aktien nicht nur aus der sicht!...sondern aufgebaut auf news ,partner ,zukunftsaussichten usw!Laut,chart-wenn,1,71$ nachhaltig durchbrochen,dann weg bis 2,16$ frei!?Denke,aber hier ist mehr zu holen!....vieleicht 5$-bis ende des Jahres??lieb,grüß-drachi

[js200]

@DRACHI

Glaube eher sie geht Richtung 1 Dollar, bevor Sie wieder hochzieht

JS200

[js200]

SECTOR(HCR): Russell 3000 Prelim Changes for July 1

Monday , June 30, 2003 12:45 ET

The following is a preliminary list of companies in the Healthcare sector which are slated for addition/deletion to the Russell 3000 Index. The list is as of June 27 and does not become official until it goes into effect July 1. The Russell 3000 Index measures the performance of the 3,000 largest U.S. companies based on total market capitalization, which represents approximately 98% of the investable U.S. equity market.

ADDITIONS:

ABRX - ABLE LABORATORIES INC
ACLA - ACLARA BIOSCIENCES INC
ALT - ALTEON INC
ASPM - ASPECT MEDICAL SYSTEMS
AVAN - AVANT IMMUNOTHERAPEUTICS
AVII - AVI BIOPHARMA INC
BLTI - BIOLASE TECHNOLOGY INC
CGPI - COLLAGENEX PHARMACEUTCLS
CLZR - CANDELA CORP
CTMI - CTI MOLECULAR IMAGING
DADE - DADE BEHRING HLDGS INC
DNDN - DENDREON CORP
DOVP - DOV PHARMACEUTICAL INC
DSCO - DISCOVERY LABORATORIES
EXAC - EXACTECH INC
GPRO - GEN-PROBE INC
GTCB - GTC BIOTHERAPEUTICS INC
HEPH - HOLLIS-EDEN PHARMACEUTCL
HITK - HI-TECH PHARMACAL INC
IMPC - IMPAC MEDICAL SYSTEMS
IRGI - INVERESK RESEARCH GROUP
ISPH - INSPIRE PHARMACEUTICALS
KFX - KFX INC
LSCP - LASERSCOPE
MDCI - MEDICAL ACTION INDS INC
MTIX - MICRO THERAPEUTICS INC
NOVT - NOVOSTE CORP
NUVO - NUVELO INC
OSTE - OSTEOTECH INC
PTN - PALATIN TECHNOLOGIES INC
RGEN - REPLIGEN CORP
RNAI - SIRNA THERAPEUTICS INC
RTIX - REGENERATION TECH INC
RVP - RETRACTABLE TECHNOLOGIES
SCLN - SCICLONE PHARMACEUTICALS
SCON - SUPERCONDUCTOR TECH
SFCC - SFBC INTERNATIONAL INC
STAA - STAAR SURGICAL CO
STAT - I-STAT CORP
SYNO - SYNOVIS LIFE TECH INC
TWTI - THIRD WAVE TECHNOLOGIES
USNA - USANA HEALTH SCIENCES
VIVO - MERIDIAN BIOSCIENCE INC
VLNC - VALENCE TECHNOLOGY INC
VSTA - VISTACARE INC
WC - WELLCHOICE INC

DELETIONS:

ABMD - ABIOMED INC
ALTH - ALLOS THERAPEUTICS INC
AMEV - APPLIED MOLECULAR EV
ARQL - ARQULE INC
ARRY - ARRAY BIOPHARMA INC
AVGN - AVIGEN INC
AVN - AVANIR PHARMACEUTICA
BRLI - BIO-REFERENCE LABS INC
BSML - BRITESMILE INC
CALP - CALIPER TECHNOLOGIES
DGEN - DELTAGEN INC
DPII - DISCOVERY PARTNERS INTL
ECSI - ENDOCARDIAL SOLUTIONS
EMBX - EMBREX INC
GZBX - GENZYME BIOSURGERY
HBIO - HARVARD BIOSCIENCE INC
HTRN - HEALTHTRONICS SURGICAL
ILMN - ILLUMINA INC
KNDL - KENDLE INTERNATIONAL
LCBM - LIFECORE BIOMEDICAL INC
MDTH - MEDCATH CORP
MEDC - MED-DESIGN CORP
MEDT - MEDSOURCE TECHNOLOGIES
NPRO - NAPRO BIOTHERAPUTICS
NRGN - NEUROGEN CORP
NSTK - NASTECH PHARMACEUTICAL
PMSI - PRIME MED SVCS INC NEW
QMED - Q MED
RGX - RADIOLOGIX INC
RIGLD - RIGEL PHARMACEUTICAL
RITA - RITA MED SYS INC DEL
RSCR - RES-CARE INC
SGMO - SANGAMO BIOSCIENCES
SNCI - SONIC INNOVATIONS INC
SQNM - SEQUENOM INC
ULGX - UROLOGIX INC
VICL - VICAL INC
WFHC - WOMEN FIRST HEALTHCARE


JS200

[js200]

NaPro BioTherapeutics Announces Results of Annual Shareholder Meeting

Monday , June 30, 2003 08:31 ET

BOULDER, Colo., Jun 30, 2003 /PRNewswire-FirstCall via COMTEX/ -- NaPro BioTherapeutics, Inc. (Nasdaq: NPRO) today announced the results of the Company`s Annual Meeting of Stockholders held June 27, 2003.


* NaPro shareholders re-elected Arthur Hayes, Jr., M.D., Robert Pollack,
Ph.D. and Leonard Shaykin to the Board of Directors.

* Shareholders approved the authorization of an amendment to effect a
reverse split of the Company`s common stock.

* Shareholders ratified the appointment of Ernst & Young as auditors.

* A shareholder proposal regarding executive compensation was defeated.


The Company also stated that its Board of Directors has determined to take no action at this time to effect a reverse split. Action on a reverse split may be reconsidered at a later date, if necessary.

About NaPro BioTherapeutics, Inc.

NaPro BioTherapeutics, Inc., is a life science company focused in two distinct areas: the development and in-licensing of targeted anti-cancer agents and the development of genomic therapies, primarily through the use of "gene editing" with additional applications in diagnostics, agribiotechnology, and pharmacogenomics.

The statements in this news release that are not historical facts are forward-looking statements that represent management`s beliefs and assumptions as of the date of this news release, based on currently available information. There can be no assurance that NaPro will be able to maintain the $1.00 minimum bid price requirement, or that NaPro will be able to meet other requirements for Nasdaq listing. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it cannot assure that these expectations will prove to be correct. These factors are more fully described in the Company`s documents filed from time to time with the Securities and Exchange Commission, which are incorporated by reference, including the Company`s Annual Report on Form 10-K and 10-K/A for the year ending December 31, 2002 filed with the Securities and Exchange Commission on March 27 and April 30, 2003, and the Company`s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 16, 2003. The Company disclaims any intention or obligation to update publicly or revise such statements whether as a result of new information, future events or otherwise.

SOURCE NaPro BioTherapeutics, Inc.


CONTACT: L. Robert Cohen, Vice President, Investor Relations of NaPro
BioTherapeutics, Inc., [phone]; or investors, Lilian Stern of Stern
Investor Relations, [phone]; or media, Linda Dyson of Signova,
[phone], both for NaPro BioTherapeutics, Inc.

URL: http://www.naprobio.com
http://www.prnewswire.com



Copyright (C) 2003 PR Newswire. All rights reserved.


-0-


KEYWORD: Colorado
INDUSTRY KEYWORD: HEA
MTC
BIO
OTC
SUBJECT CODE: PER
OTC


STOCK SYMBOLS: [(npro)]

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


06/30/2003 (12:45 ET) SECTOR(HCR): Russell 3000 Prelim Changes for July 1 - Knobias



06/30/2003 (08:31 ET) NaPro BioTherapeutics Announces Results of Annual Shareholder Meeting - PR Newswire



06/27/2003 (08:02 ET) PRE 14A: NPRO Vote; Directors; Rev Stock Split; Auditor - Knobias



06/25/2003 (11:32 ET) NPRO President to Speak at BIO 2003 Today @ 2:30 PM ET - Knobias



06/25/2003 (09:30 ET) NaPro advances its sickle cell program with two research collaborations - Datamonitor



06/24/2003 (19:20 ET) NPRO: Short Interest UP 14.6% to 1.2M in Jun 2003 - Knobias



06/24/2003 (11:07 ET) NPRO Enters Alliances to Advance Sickle Cell Program - Knobias



06/24/2003 (08:31 ET) NaPro Advances Its Sickle Cell Program With Two Research Collaborations - PR Newswire



06/18/2003 (08:30 ET) NaPro BioTherapeutics to Webcast Gene-Editing Presentation At BIO 2003 Annual Convention - PR Newswire



06/16/2003 (08:30 ET) NaPro BioTherapeutics Regains Compliance With Nasdaq Small Cap Market Bid Price Requirements - PR Newswire



06/10/2003 (08:49 ET) Wall Street News Alert Announces Investment Opinion: Moneymaker Hits the Jackpot! - Internet Wire



06/09/2003 (09:32 ET) NaPro`s gene editing demonstrates gene alteration in human cells - Datamonitor



06/09/2003 (09:03 ET) NPRO Shows 40% Longer Life for Neuronal Cells in Study - Knobias



06/08/2003 (08:01 ET) NaPro`s Technology Extends Life of Neuronal Cells By Up to 40% in Huntington`s Disease Model - PR Newswire

JS200

[drachentier]

Danke!...Du,machst mir ja Hoffnung!?Glaube,Trotzdem dieses Jahr noch an mehrere gute News!...Umsätze,der firma steigen Kontinuierlich,...fallen,die Aktien noch ma wird eben nachgekauft!Kannst,mich idiot nennen,aber ich bin Überzeugt von der Firma!!...lieb,grüß-Drachi

[Heinerle2]

@16: Sehe ich auch so, bin bereits gut positioniert, Richtung 1.90-2.00 denke ich dann evtl. mal über einen Exit nach

Greetinxx Heinerle2

[drachentier]

was haltet Ihr von den Quartalszahlen?...lieb,grüß-drachi.

[Heinerle2]

Sodele, meine Stücke sind weg, gleich zur Eröffnung - hatte noch ein altes Limit drin aus meiner Vor-Urlaubs-Zeit - und heute noch nicht gestrichen

Greetinxx Heinerle2

[castafiore]

wollte napro nur mal wieder in erinnerung bringen.
casta

[Strait1]

Jo, danke für die Erinnerung.
Heute tut sich irgendwas.

Bye
S.

[Strait1]

NaPro Completes Sale of Worldwide Paclitaxel Business to Mayne Pharma



BOULDER, Colo., Dec. 12 /PRNewswire-FirstCall/ -- NaPro BioTherapeutics, Inc.(NASDAQ-SMALL:NPRO) (Nasdaq: NPRO) announced today that it has completed the sale of its worldwide generic injectable paclitaxel business to Mayne Pharma for $71.7 million in cash minus an inventory adjustment of $4.6 million to reflect NaPro`s actual inventory as of the date of closing. The proposed sale of the paclitaxel business was first announced by NaPro on August 26, 2003. Stockholders approved the sale at a special meeting of stockholders held today.

NaPro retired $21.9 million in debt (including accrued interest) and payables arising from its development relationship with Abbott Laboratories(NYSE:ABT) , and received $3.2 million in connection with the termination of its marketing agreements with Mayne Pharma and Abbott. NaPro expects that its cash balance at year end will be approximately $50 million.

"The net proceeds from this sale, to our long standing partner Mayne Pharma, will provide us with additional capital to advance the development of our proprietary oncology and hereditary disease therapeutic programs," commented Leonard P. Shaykin, Chairman and CEO. "We anticipate bringing at least two of our proprietary drug candidates into the clinic in the coming year."

The closing of the paclitaxel sale marks the termination of NaPro`s development agreements with Mayne Pharma. On September 30, 2003, Mayne Pharma announced that it had acquired Abbott Laboratories`(NYSE:ABT) marketing and distribution rights for paclitaxel in North America and along with it, Abbott Laboratories`(NYSE:ABT) holdings of two million shares of NaPro`s common stock.

[tomtom11]

Hallo,

verstehe nicht, dass sich niemand um Napro schert.
Sieht doch gar nicht schlecht aus.

Grüße an alle Investierten.

t.t.

[Strait1]

Stillstand

[Strait1]

Was ist seit gestern los ?

[castafiore]

kein stillstand mehr!
bin jetzt + - 0 endlich. nun gehts ans verdienen.
casta

[castafiore]

n.s.
einen so klassisch schönen 6-monats-chart wie bei napro habe ich schon lange nicht mehr gesehen - wie aus dem lehrbuch.
casta

[Strait1]

Ich brauch noch was, hatte bei 2,50 gekauft.

Weiss denn jemand was los ist ?
Stehen News oder Zahlen an ?

Bye
S.

[castafiore]

sieht einfach nur gut aus!
casta

[castafiore]

na ja heute nicht ganz so gut.
scheint, dass ich mich mit mir selbst unterhalte.

casta

[Strait1]

Rein in die Kartoffeln, raus aus den Kartoffeln.

[castafiore]

und wieder rein!
casta

[Strait1]

... und wieder raus.

[castafiore]

dann waren das deine 50 stück?
casta

[Strait1]

Wäre froh nur 50 zu haben, leider sind es mehr.
KK noch nicht erreicht.

[Strait1]

Sehen wir heute oder morgen die 3 $ ?

[castafiore]

morgen auf alle fälle - hoffentlich nachhaltig
casta

[Strait1]

+ 8,15 % an der Nasdaq.

3 $ wir kommen !

[castafiore]

ja wir schleichen uns an die 3 ran. super chartbild - wie aus dem musterbuch.
casta

[Strait1]

3 $ geknackt !!!

[Strait1]

3,14 $

Oh happy day !

[Strait1]

3,22 $

[castafiore]

strait1
wir sind in d wohl die einzigen shareholder oder?
schade, dass keiner ausser uns sowas sieht!
casta

[Strait1]

@casta

Ich bin so froh Dich zu haben.
Bei Brocade bin ich nämlich Alleinunterhalter.

[Strait1]

NaPro BioTherapeutics platziert zwei Millionen eigene Aktien

Das amerikanische Biotechnologieunternehmen NaPro BioTherapeutics Inc. kündigte am Freitag die Veräußerung von insgesamt 2 Millionen eigenen Aktien an, welche zu einem Preis von jeweils 2,60 Dollar bei zwei institutionellen Investoren platziert werden sollen.

Die Verkaufserlöse sollen Unternehmensangaben zufolge zur Weiterentwicklung neuer Produkte sowie zur Finanzierung möglicher Lizenzabkommen verwendet werden.

Die Aktie von NaPro BioTherapeutics schloss an der NASDAQ zuletzt bei 2,96 Dollar.

[castafiore]

tolle wurst!
da denkt man, endlich sind die 3,- genommen - und dann sowas!
ich bin nun doch genervt. andererseits, wenn institutionelle sich beteiligen, kann das ja nur gut sein.
also - long bleiben.
casta